TRIPASS XR تري باس

 

IV methylprednisolone, 728

IV pentamidine isethionate, 1603

IV tobramycin, 462

IV verapamil, 345

Ixabepilone, 469t

peripheral nerve toxicity of, 1986

Ixazomib, 470t

Ixekizumab, 842–843

Ixempra (see Ixabepilone)

J

Jevtana (see Cabazitaxel)

K

Kalydeco (see Ivacaftor)

Kanamycin, teratogenic effects, 973t

Kaolin-pectin, 2161

Keflex (see Cephalexin)

Keppra, 1285t

Keratolytics, 835t

Ketamine, 1182, 1885, 2131t

for pediatric intubation, 2200t

Ketek (see Telithromycin)

Ketoconazole, 120t, 128, 484, 485, 486, 942t, 1624t, 1625, 1633, 1637, 1639, 1640

antifungal agent, 41, 2093

adverse effects of, 1334t

for chronic pulmonary blastomycosis, 1637

CNS penetration of, 1640

Ketoprofen, 870t

Ketorolac (Acular), 439t, 870t, 887, 888t

Ketotifen, 439t, 1165

Kinrix, 1356t

KOH (see Potassium hydroxide (KOH))

Kyleena, 948

Kytril (see Granisetron)

L

Labetalol (Normodyne; Trandate), 335t, 336t, 985t, 986

for BP, 339, 346

disadvantages of, 343

for hypertension, 158–159, 159t, 340, 343

parenteral to oral conversion, 343

for pregestational diabetes, 979

Lacosamide, 1181t, 1279t, 1281, 1285t

Lactogen, 980

Lactulose, 2159t

hepatic encephalopathy, 553

and neomycin, 553–554

and rifaximin, 553

LAIV (see Live attenuated influenza vaccine)

Lamictal (see Lamotrigine)

Lamivudine, 1679, 1680

for HBV, 1678

for HIV, 1577t

in labor, 996, 997

-related anemia, 1944

Lamotrigine, 942t, 1181t, 1187t, 1191, 1279t, 1281, 1845, 1846–1847, 1849t

for absence seizures, 1290–1291, 1291t

and carbamazepine, 1286–1287

for diabetes, 1145

for schizophrenia, 1809

for seizures, 1284t, 1286–1287

teratogenic effects, 973t

Lansoprazole, 483t, 484, 485, 502, 515t, 871, 1216t, 2163t

Lanthanum, 620t

Lanthanum carbonate, 620–621

Lantus (see Insulin glargine)

Lapatinib, 128, 470t, 1990, 2057

L-asparaginase, 2020t

Lastacaft (see Alcaftadine)

Latanoprost (Xalatan), 1151

Latuda (see Lurasidone)

L-Carnitine, 169, 659, 961

Lecithin, for RDS, 2170

Ledipasvir, for HAV, 1688, 1689

Leflunomide, 708, 712t, 713t, 881, 882

adverse effects, 893–894

and cholestyramine, 894

dosage, 893

Lenalidomide, 470t, 1972, 1991t, 2037t, 2038

neurotoxicity of, 1985t

peripheral nerve toxicity of, 1986

Lenvatinib, 470t

Lepirudin

antithrombin product, 656

for heparin-induced thrombocytopenia, 178

Letrozole (aromatase inhibitor), 960, 1012t, 1013

Leucovorin, 1992, 2009–2010

for Toxoplasma encephalitis, 1605–1606

Leukeran (see Chlorambucil)

Leukotriene

for EIA, 401

modifiers, 459

for allergic rhinitis, 433

for asthma, 397

modifying agent therapy

for rhinitis, 442–443

for rhinitis, 442–443

Leuprolide (Lupron), 1020t, 1021

for prostate cancer, 2094

Levalbuterol, for COPD, 419, 420t

Levemir (see Insulin detemir)

Levetiracetam, 1279t, 1281, 1845

for seizures, 1285t, 1287, 2192

Levobunolol (Betagan), 1151

Levocabastine, 1165

Levocetirizine (Xyzal), 433t

for rhinitis, 437

Levodopa, 1250t

and adjunctive therapy, 1259

drug interactions, 1261t

metabolism in human body, 1259f

for Parkinson’s disease, 1252–1253, 1257–1258, 1261

for RLS, 1269

Levofloxacin (Levoquin), 494t, 1326t

for aerobic gram-positive cocci, 1326t

for CAPD-associated peritonitis, 1476t

for COPD, 424

dosing of, 1337t

for skin and soft tissue infections, 1550

for travelers’ diarrhea, 1461t

for tuberculosis, 1430t

for UTI, 1488t, 1497t

Levomilnacipran

for depressive disorders, 1819t, 1821t

for serotonin, 1826

Levonorgestrel, 936–938t, 948, 951

Levonorgestrel intrauterine system (IUS), 1016

Levonorgestrel-releasing IUD (Mirena), 948, 1033t

p. 2305

p. 2306

Levoquin (see Levofloxacin)

Levosimendan, 267

Levothyroxine (L-thyroxine), 88, 127, 942t, 971, 974, 1039–1040, 1041t, 1049, 1056

Lexapro (see Escitalopram)

Lialda (see Mesalamine)

Lidocaine, 484, 1177t, 1187t, 1975, 2131t

for cardiopulmonary arrest, 331

patches (Lidoderm), 1182t, 1190, 1654

topical, 1654

for ventricular arrhythmias treatment, 248

Lidoderm (Lidocaine patches), 1654

Liletta, 948

Linaclotide (Linzess), 535

Linagliptin, 1127–1128

Lindane, 1705t, 1711

toxicity, 1711

Linezolid (Tedizolid, Zyvox), 1325t, 1393

adverse effects of, 1333t

for aerobic gram-positive cocci, 1326t

for CAPD-associated peritonitis, 1476t

for CNS infections, 1373t

dosing of, 1337t

for endocarditis, 1396, 1399

for HAP, 1418–1419

MRSA, 1550

for skin and soft tissue infections, 1549

with vancomycin, 1564

Linzess (see Linaclotide)

Liotrix, 1049

Lipid-lowering agents, 258

Lipopeptides, 1625

Liquid multivitamin, 457

Liraglutide (Saxenda), 764, 1126–1127, 1139

Lisdexamfetamine, for ADHD, 1868t

Lisinopril, 41, 281–282, 281t, 2223

in hypertension, 153t

for prostate cancer, 2086, 2094

Lispro, 980

Lithium, 214, 579, 1837

and ACE inhibitors, 1843t

and acetazolamide, 1843t

and acne, 1841t

adverse effects, 1841–1842, 1841t

and antipsychotics, 1843t

for bipolar depression, 1846, 1848

for bipolar disorder, 1849t

and caffeine, 1843t

and carbamazepine, 1843t

for critically ill patients, 1208

for depressive disorders, 1817

and diltiazem, 1843t

and diuretics, 1843t

dosage, 1841

drug–drug interactions, 1843t

drug–food interactions, 1843

half-life of, 1841

and hypothyroidism, 1842–1843

and lactation, 1003t

and methyldopa, 1843t

monitoring of, 1840t

and NSAIDs, 1843t

patient education, 1842

during pregnancy, 1843–1844

prelithium workup, 1840

psoriasis and, 833

for schizophrenia, 1809

and sodium, 1843t

and SSRIs, 1843t

teratogenic effects, 973t

and theophylline, 1843t

toxicity, 1842

and verapamil, 1843t

weight gain with, 1843

Lithium carbonate, 1244

Lithium–lamotrigine, 1847

Live attenuated influenza vaccine (LAIV), 1361

Lixivaptan, 579–580

LMWHs (see Low-molecular-weight heparins (LMWHs))

Local anesthetics, 1187t

for neuropathic pain, 1188

for pain management, 1177t

Lodoxamide (Alomide), 439t, 1165

Lomitapide, 120t

adverse effects, 127–128

clinical pearls, 128

drug interactions, 128

efficacy, 127

mechanism of action, 127

pharmacokinetics/pharmacodynamics, 127

place in therapy, 127

Lomustine, 470t, 1991, 1991t

Loniten (see Minoxidil)

Loop diuretics, 580

and AIN, 645

dosing, 270t

for hypertension, 140, 148, 149t

and hypokalemia, 583t

Loperamide, 1976

antidiarrheals, 536

diarrhea and, 1458

for infectious diarrhea, 1449

for travelers’ diarrhea, 1460

Lopinavir/ritonavir, 120t, 128, 942t

for HIV, 1579t

for SARS, 1660

Lorabid (see Loracarbef)

Loracarbef (Lorabid), 1326t

Loratadine (Claritin), 433t

for rhinitis, 437

and sleep, 1766

Lorazepam (Ativan), 55, 472t, 988, 1737t

for acute agitation, 1846

for Akathisia, 1800t

alcohol withdrawal, 1896

for end-of-life care, 89

for LTCF, 2229

for pediatric intubation, 2199t

for schizophrenia, 1793t

in SE, 1299

Lorazepam IV, for seizures, 2192

Lorcaserin (Belviq), for obesity, 763–764

Losartan, 55, 171, 257, 284, 918, 923–924

Losartan potassium, 154t

Loteprednol (Alrex), 439t

Lovastatin, 46t, 110t, 116, 117t, 120t, 125

for end-of-life care, 88

Lovaza, 126

Low-dose aspirin therapy, 144

Low-molecular-weight heparins (LMWHs), 176, 177t

advantages of, 237

with renal impairment, 188t

for thrombosis, 177

UFH and, 177t

Loxapine, 1789t, 1797t, 1799t

for schizophrenia, 1785, 1788

LSD (see Lysergic acid diethylamide (LSD))

L-thyroxine (see Levothyroxine)

Lubiprostone, 535

Lugol’s solution, 1058, 1059t, 1065

for thyroid storm, 1067

Luliconazole, 914t

Lumacaftor, CFTR corrector, 452

Lumigan (see Bimatoprost)

Lumiracoxib, 870

Lunesta (see Eszopiclone)

Lupron (see Leuprolide)

Lurasidone (Latuda), 1797t, 1799t, 1847

for bipolar depression, 1847t, 1849t

for hyperprolactinemia, 1803

for schizophrenia, 1790, 1791t

Luvox (see Fluvoxamine)

Lyrica (see Pregabalin)

Lysergic acid diethylamide (LSD), 1003t, 1885

for schizophrenia, 1783, 1783t

Lytic peptides, 1626

M

Macrolides, 1549

adverse effects of, 1332t

for inflammatory response in CF, 459

for MAC, 1619

fo

r

s

kin

a

n

d

s

o

ft

t

is

s

u

e

in

fe

c

t

io

n

s

,

1

5

4

9

M

a

fe

n

i

d

e

a

c

e

t

a

t

e

(

S

u

l

fa

m

yl

o

n

)

,

8

6

3

M

a

g

n

e

s

i

u

m

,

2

7

,

6

2

1

,

9

8

8

,

1

9

8

6

–

1

9

8

7

a

n

d

a

luminum

a

nt

a

c

id

s

,

4

8

2

,

4

8

4

a

n

d

c

h

ildr

e

n

,

2

1

4

0

t

fo

r

dy

s

me

n

o

r

r

h

e

a

,

1

0

1

5

a

n

d

in

du

c

t

io

n

th

e

r

a

p

y

,

1

6

1

2

fo

r

n

o

r

ma

l

s

inu

s

r

hythm

,

3

2

8

fo

r

P

M

S

,

1

0

2

4

a

n

d

p

r

e

gn

a

n

c

y

,

9

6

8

a

n

d

r

e

s

p

ir

a

t

o

r

y

a

lka

lo

s

is

,

1

6

7

2

M

a

g

n

e

s

i

u

m

c

h

o

l

i

n

e

s

a

l

i

c

yl

a

t

e

,

8

8

8

t

M

a

g

n

e

s

i

u

m

h

y

d

r

o

x

i

d

e

,

6

2

0

t

,

2

1

5

9

t

M

a

g

n

e

s

i

u

m

s

u

l

fa

t

e

,

9

8

8

,

9

9

2

,

1

7

1

0

M

a

i

n

t

e

n

a

n

c

e

t

h

e

r

a

p

y

,

1

6

0

8

–

1

6

0

9

t

,

1

7

5

9

,

1

8

4

1

,

2

0

1

7

–

2

0

1

8

fo

r

A

I

D

S

,

1

6

1

5

fo

r

B

D

,

1

8

4

8

–

1

8

5

0

fo

r

C

M

V

,

1

6

0

1

,

1

6

0

7

,

1

6

1

2

–

1

6

1

3

fo

r

GE

R

,

2

1

6

4

fo

r

H

B

V

,

1

6

8

0

fo

r

I

A

,

2

1

2

5